Wereport here a patient with myelodysplastic syndromes (MDS), which was complicated with several autoimmune disorders and asymptomatic immunologic abnormalities.
Introduction
Myelodysplastic syndromes (MDS)are clonal hematopoietic stem cell disorders characterized by hypercellular bone marrow with multi-lineage dysplasia, and peripheral cytopenia as a result of ineffective hematopoiesis. Complications of immunologic abnormalities, especially autoimmune disorders, have been reported to be rather frequent in patients with MDS (1) 
Addison's disease is also occasionally observed in patients with various autoimmune disorders. For example, the combined occurrence of Addison's disease with either type I diabetes mellitus or Hashimoto's thyroiditis is well knownas a polygrandular syndrome type II, also knownas Schmidt syndrome (2) . However, the hematological disorders (except for pernicious anemia) are rarely observed in patients with Addison's disease. Here, we report a case of MDS-refractory anemia (RA) with Addison's disease. This case further showed several other autoimmune disorders and asymptomatic serological abnormalities, which were all cured after steroid therapy.
For editorial comment, See p 985.
Case Report
In April 1997, an 82-year-old woman with a 2-year history of thrombocytopenia (37x109//) was referred to our hospital. She had been treated for hypertension, but had no other medical history or blood transfusions. Her bone marrow (BM) findings showed hypercellularity with low blast cell counts and the trilineage dysplasia of hematopoietic cells. A cytogenetic analysis of BMcells revealed a normal karyotype. At this time, we had diagnosed the patient as having refractory anemia (RA) based on the diagnostic criteria of the French-American-British classification of MDS(3). In addition, she was classified into a low risk group of MDSaccording to the international prognostic scoring system (IPSS) (4). Twenty-twomonths later, she was hospitalized because of the progression of thrombocytopenia (5x l O9//) and increasing sense of fatigue, anorexia, and weight loss (-7 kg for 24 months). On admission, she showed pale conjunctiva, pigmentation of the systemic skin and oral cavity (Fig. 1) , and petechiae on her foot. Her MPand PIPjoints were slightly swollen and deformed. Low blood pressure (96/48 Torr) was also observed. There was no hepatosplenomegaly. A complete blood count showed a hemoglobin level of 10.2 g/dl, a platelet count of 3xl09//, and white blood cell count of 3.5xl09// with 5 1 % neutrophils, 9% eosinophils, 29% lymphocytes, and 11%monocytes. A BMaspirate on admission revealed a hypercellular marrow with megakaryocytic hyperplasia (Fig. 2) . The percentage of blasts in the BMwas 3.6%. A chromosomal analysis showed a normal karyotype. These he-matological findings were consistent with RAin MDS.She was still scored as a low risk group according to IPSS (4). Since the platelet-associated IgG (PAIgG) was extremely elevated at 1 1 ,466.7 ng/107 cells, the megakaryocytic hyperplasia was also suggestive of autoimmune thrombocytopenia. In addition, laboratory findings such as a positive result for Coombs' test, an increased indirect bilirubin level (0.88 g/dl), low level of serum haptoglobin (<10 mg/dl), an elevated reticulocyte count (1.7%) and erythroid hyperplasia in BM(L/E=1.47) all suggested that she also had autoimmunehemolytic anemia. Endocrine investigations showed a lack of serum cortisol (<1.0 | ig/dl) and a highly elevated ACTHconcentration (1 , 100 pg/ml). Her serum aldosterone concentration was decreased to 37 pg/ml, the lower limit of the normal range (normal <36 to 240). The plasma renin level was 0.7 ng/ml/h (normal <0.3 to 2.9). These results confirmed the coexistence of primary adrenocortical insufficiency with MDS.A thin-slice scanning of abdominal computed tomography (CT) showed no abnormal morphological changes in the bilateral adrenal glands. In addition to these CTfindings, no past history of tuberculosis, and no calcification of the adrenal gland indicated that tuberculosis was not thought to be the cause of adrenal insufficiency.
Her physical findings, such as systemic pigmentation and low blood pressure, were also consistent with the symptomsof
Addison's disease. Furthermore, rheumatoid factor (RF) was MDSand Addison's Disease positive at a titer of 1: 32 and RAPAwas 1: 64. Serum C-reactive protein was 1.3 mg/dl and the erythrocyte sedimentation rate was 30 mm/h. The swelling of the finger joints, morning stiffness and the radiographic findings of these joints all supported the diagnosis of rheumatoid arthritis with a low activity. Her serum total protein measuring 6.8 g/dl was within the normal range. However, she showed a polyclonal gammopathy which was 27.2% of y-globulin fraction in whole serum. Decreased complementcomponents were also detectable. Diabetes mellitus, and thyroid or parathyroid dysfunction were not seen. A prolongation of APTTdue to circulating anticoagulants was also observed.
Thereafter, the patient was orally treated with 25 mg/day (0.6 mg/kg) of prednisone. After the initiation of steroid therapy, her anemia improved rapidly in accordance with increased haptoglobin and decreased birilubin levels. Thrombocytopenia was also improved with disappearance of PAIgG. In addition, autoimmunemanifestations such as hyperpigmentation, anorexia, and weight loss were clearly improved, and the ACTHlevel was dramatically normalized. After reducing the steroids to 5 mg/day, the complete resolution of all clinical manifestations, including cytopenia has been maintained over one year to date.
Discussion
In MDSpatients, various immunological abnormalities have been reported relatively frequently. Ten to twenty percent of MDSpatients have been reported to have accompanying autoimmune disorders (2, 5, 6) . This high incidence implies a non-fortuitous association between MDSand autoimmune disorders. Yet, the pathophysiologic basis of MDSfor autoimmunity is still unknown. Conversely, it is also well known that Addison's disease is frequently found in association with other autoimmune disorders (7).
In MDS,skin rashes of an autoimmune etiology are particularly commonamong the complications reported (1). In addition, autoimmunecomplications such as rheumatoid arthritis, autoimmunehemolytic anemia, and a wide variety of vasculitic conditions represented by cutaneous vasculitis, Sweet syndrome, pyoderma gangrenosum and Beh9et syndrome (8) were also reported in cases of MDS,which are likely to be a consequence of immunological derangement of MDSwhich is possibly derived from the MDSclone (1). Determining the origin of MDSclone, since most transformation of MDSinto acute leukemia is myeloid, it is suggested that the MDSclone is a myeloid progenitor cell (9) . On the contrary, there are several reports of acute lymphoblastic leukemia (ALL) transformation of MDSof all subtypes (10) . Thus, it is still not clear whether these immunologic abnormalities are caused by abnormal lymphocytes derived from the MDSclone or by the indirect effects of abnormal cytokine-production and antigen-presentation by the disordered monocytes ( 1) . In addition, asymptomatic immunologicabnormalities are also frequent in patients with MDS.In the present case as well, a gammopathy, the presence ofANA,and a positive result for direct Coombs' test are reported as the most commonfeatures (5). However, as far as we know, Addison's disease has not been reported as a complication of MDS.
It has been reported that autoimmune disorders maybe the primary cause of death in some MDSpatients. Nevertheless, howthe association with autoimmunedisorders influences the prognosis for MDSpatients is still unclear. It has been reported that the mediansurvival duration of all MDS patients was 25 months, whereas it was 9 months for the MDSpatients accompanied by autoimmunemanifestations, suggesting a poor prognosis ( 1 1). In contrast, another report demonstrated that complicated autoimmune manifestations did not influence the prognosis for MDS (6) . However, it is noteworthy that all these immunologic disorders have been reported to show a good response to immunosuppressive therapy (2, 5 
